These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical experience with sulprostone (author's transl)].
    Author: Brabec W, Dapunt O, Bichler A.
    Journal: Wien Klin Wochenschr; 1981 Mar 20; 93(6):193-7. PubMed ID: 7281695.
    Abstract:
    Sulprostone (SHB 286, Schering) was used for the induction of abortion mainly in patients with missed abortion, but also in cases of intrauterine death and hydatid mole (total number: 226). In the first trimester a single injection of 25 or 50 mcg into the cervix ("intramural" injection) in order to obtain preoperative dilatation of the cervix was favoured. In the second and third trimester Sulprostone was administered by the intravenous (mean dosage 925 mcg), the intragluteal (mean dosage 540 mcg) or the extra-amniotic (mean dosage 660 mcg) route. After "intramural" administration an abortion score of at least 20 according to Csapo was obtained in 78% of patients. With the intravenous route the abortion rate was 86%, with the extra-amniotic 74% and with the intragluteal route 70%. The main use of "intramural" application is seen in the first 12 weeks of pregnancy in order to ensure non-traumatic dilatation of the cervix. In the second and third trimester intravenous and intragluteal administration seem to be superior to the extra-amniotic route because of their better tolerance. Sulprostone (SHB 286, Schering) was used in patients with missed abortion as well as in cases of intrauterine death and hydatid mole (total number=226). In the 1st trimester, a single injection of 25 or 50 mcg was administered into the cervix in order to accomplish preoperative dilatation of the cervix (intramural injection). In the 2nd and 3rd trimesters, Sulprostone was administered either by intravenous (mean dosage, 925 mcg), intragluteal (mean dosage, 540 mcg), or the extraamniotic (mean dosage 660 mcg) routes. After intramural administration, an abortion score of at least 20 according to Csapo was obtained in 78% of the patients. With an intravenous route, the abortion rate was 86%, with an extraamniotic route 74%, and with the intragluteal route 70%. The main use of intramural applications is seen the first 12 weeks of pregnancy in order to ensure nontraumatic dilatation of the cervix. In the 2nd and 3rd trimesters, intravenous and intragluteal administration seem to be superior to the extraamniotic route due to the increased tolerance. (author's)
    [Abstract] [Full Text] [Related] [New Search]